Sequoia Financial Advisors LLC Decreases Stake in Merck & Co., Inc. $MRK

Sequoia Financial Advisors LLC lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 1.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 292,117 shares of the company’s stock after selling 4,929 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Merck & Co., Inc. were worth $37,537,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. California State Teachers Retirement System grew its stake in Merck & Co., Inc. by 12,537.4% during the second quarter. California State Teachers Retirement System now owns 484,720,247 shares of the company’s stock worth $62,286,552,000 after buying an additional 480,884,635 shares during the period. Norges Bank purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at $3,997,933,000. Wellington Management Group LLP raised its stake in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Cardano Risk Management B.V. acquired a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $1,012,530,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Merck & Co., Inc. by 37.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock valued at $1,973,983,000 after acquiring an additional 5,152,069 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $147.69 on Thursday. The firm has a fifty day simple moving average of $135.91 and a 200-day simple moving average of $124.10. The company has a market capitalization of $364.37 billion, a PE ratio of 118.15, a price-to-earnings-growth ratio of 6.46 and a beta of 0.21. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades support valuation: Leerink Partners raised its price target from $127 to $161 and maintained an “outperform” rating, while Guggenheim increased its target from $146 to $170 and assigned a “buy” rating. The revisions suggest analysts see further upside from Merck’s commercial execution and pipeline. Benzinga analyst rating reports
• Positive Sentiment: Pipeline expansion addresses the Keytruda patent cliff: Merck is pairing antibody-drug conjugates (ADCs) with Keytruda in women’s cancers, seeking to improve outcomes in difficult-to-treat tumors while building future revenue sources before Keytruda faces patent pressure. Merck pairs ADCs with Keytruda in women’s cancer push
• Neutral Sentiment: Investor attention is focused on management commentary: Merck presented at the Wells Fargo 21st Annual Healthcare Conference and is scheduled to participate in Morgan Stanley’s global healthcare conference. These events may provide additional detail on Keytruda demand, pipeline progress and long-term growth plans. Wells Fargo healthcare conference transcript
• Neutral Sentiment: Keytruda and new products remain central to the bull case: Commentary highlights Keytruda’s current growth contribution and Merck’s efforts to develop products capable of extending momentum beyond the anticipated 2028 patent cliff. MRK’s strong recent performance and elevated valuation leave expectations high. Merck trading near 52-week high
• Negative Sentiment: Long-term patent risk remains: Investors are watching whether Merck can replace revenue that may be lost when Keytruda’s exclusivity weakens. The company’s ability to commercialize ADC combinations and other pipeline assets is therefore critical to sustaining growth and its current valuation. Merck outlook and GARDASIL commentary

Analyst Ratings Changes

Several analysts recently issued reports on the company. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a report on Wednesday, August 12th. Royal Bank Of Canada cut Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and boosted their price objective for the stock from $142.00 to $150.00 in a research note on Thursday, August 20th. Weiss Ratings raised Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 25th. Wells Fargo & Company increased their target price on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Finally, Barclays raised their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Sixteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus target price of $150.33.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 228,238 shares of company stock valued at $29,977,783. Insiders own 0.17% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.